Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on August 13, 2018, covering the earliest event date of August 9, 2018. The Company is incorporated in Delaware and maintains its principal executive offices in Carmiel, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
- Appointment: On August 9, 2018, the Board appointed Mr. David Granot as an independent director.
- Committee Assignment: Mr. Granot was simultaneously appointed to serve on the Company's Audit Committee.
- Announcement: A press release detailing this appointment was issued on August 13, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director appointment.
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed director, Mr. David Granot.
- Confirm the composition of the Audit Committee following Mr. Granot's appointment.
- Review the attached press release (Exhibit 99.1) for additional context regarding the appointment.